FOR THE FIRST TIME IN EUROPE !
In February 2017, the Agence Nationale de Sécurité du Médicament (ANSM) issued 3 Primo-Conformities to Good Laboratory Practice (GLP) of Status A at the end of a non-clinical Multisite study involving academic and private Toulouse establishments.
As part of the Toulouse regenerative medicine field, included in the Regional Innovation Strategy, STROMALab and LabHPEC (Laboratoire d’HistoPathologie Expérimentale et Comparée) are embarking on the GLP adventure to conduct non-clinical regulatory trials for cell therapies. These actors take on board with them two other organisations, one academic (CREFRE, Inserm’s zootechnics service) and the other private (Scanelis, PCR analysis laboratory). The study carried out is a biodistribution and toxicity study of ASC (mesenchymal stem cells originated from fat) which was sponsored by STROMAlab as part of the ECellFrance platform (future investment financing).